Jennifer Wellman - Spark Therapeutics Insider

Spark Therapeutics Inc -- USA Stock  

USD 62.41  2.96  4.53%

Co-Founder and Head of Regulatory Strategy

Ms. Jennifer Wellman is CoFounder and Head of Regulatory Strategy of Spark Therapeutics Inc. Prior to joining Spark Ms. Wellman was the Director of Regulatory Interactions for Gene Therapy Studies at the Center for Cellular and Molecular Therapeutics at CHOP. Ms. Wellman also previously held a role as Associate Scientist at Avigen Inc
Age: 36  Founder Since 2013      
Wellman holds a B.S. in microbiology and immunology from Queen?s University and an M.S. from the University of New Haven.

Management Efficiency

The company has return on total asset (ROA) of (29.55) % which means that it has lost $29.55 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (60.07) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 36.22 M in liabilities with Debt to Equity (D/E) ratio of 7.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Spark Therapeutics Inc has Current Ratio of 9.73 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. Spark Therapeutics operates under Biotechnology classification in USA and traded on NASDAQ. It employs 315 people.Spark Therapeutics Inc (ONCE) is traded on NASDAQ in USA. It is located in PENNSYLVANIA, U.S.A and employs 315 people. Spark Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.

Fix Portfolio

Optimize Your Risk-Return Tradeoff
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Spark Therapeutics Inc to your portfolio

Top Management

Spark Therapeutics Inc Leadership Team
Romuald Corbau, Executive
Carol GrevePhilips, Executive
Robert Perez, Director
Lars Ekman, Director, Ph.D
Jennifer Wellman, Founder
Fraser Wright, Founder, Ph.D
Morgan Molloy, Executive
Lorris Betz, Director
Joseph Barge, Executive
Katherine High, President, Ph.D
Elliot Sigal, Director
John Furey, COO, MBA
Vincent Milano, Director
Lota Zoth, Director
Rogerio Coelho, Executive
Elliott Sigal, Director
Guang Qu, Executive
Daniel Takefman, Executive, Ph.D
Stephen Webster, CFO, MBA
Rogerio Vivaldi, Executive
Diane Blumenthal, Executive, MBA
Jeffrey Marrazzo, CEO, MBA
Daniel Faga, Executive, MBA
Anand Mehra, Director
Linda Hearne, Executive, MBA
Paul Gil, Executive, MBA
Charles Sigal, Director
Federico Mingozzi, Executive
Steven Altschuler, Chairman
Lisa Dalton, Executive, MBA

Stock Performance

Spark Therapeutics Performance Indicators